On July 15, Genscript Biotech rose 5.04% in regular trading, trading at HK$15.0 per share, with turnover of HK$206 million. The rally was driven by the ongoing CXO sector interim results window, where multiple brokerages noted that the digestion of earlier low-price orders has confirmed a dual inflection point in both revenue and profit for the industry, further strengthening the valuation recovery thesis.

Data from 22 listed CXO companies showed first-quarter revenue and net profit grew 18.6% and 21.9% year-over-year respectively, with domestic CXO firms reporting ample orders and improving volume-price dynamics. As the global leader in gene synthesis and a core CRDMO platform for biologics, Genscript benefits from the broader industry recovery and expanding AI-driven drug discovery demand.

Within the Life Sciences Tools and Services sector, peers also posted strong gains, with JOINN up 17.66%, Insilico up 10.64%, Pharmaron up 9.24%, WuXi AppTec up 5.19%, and WuXi Biologics up 4.61%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)